Utvasking ved skifte av MS behandling
Sist revidert:
Sist revidert av:Øyvind Torkildsen, spesialist i nevrologi
- Iaffaldano P1, Lucisano G2, Pozzilli C3, Brescia Morra V4, Ghezzi A5, Millefiorini E6, Patti F7, Lugaresi A8, Zimatore GB9, Marrosu MG10, Amato MP11, Bertolotto A12, Bergamaschi R13, Granella F14, Coniglio G15, Tedeschi G16, Sola P17, Lus G18, Ferrò MT19, Iuliano G20, Corea F21, Protti A22, Cavalla P23, Guareschi A24, Rodegher M25, Paolicelli D1, Tortorella C1, Lepore V26, Prosperini L3, Saccà F4, Baroncini D5, Comi G25, Trojano M; Italian iMed-Web database.. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain 2015; Nov;138(Pt 11):: 3275-86. pmid:26362907 PubMed
- . Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist.. Neurol Clin Pract. 2019; Feb;9(1): 53-63. pmid:30859008 PubMed
- Øyvind Torkildsen, spesialist i nevrologi, professor PhD
- Unn Ljøstad, spesialist i nevrologi, professor PhD
- Åse Mygland, spesialist i nevrologi, professor dr med